Biochip detection of KRAS, BRAF, and PIK3CA somatic mutations in colorectal cancer patients

摘要: Somatic mutations of KRAS, PIK3CA, and BRAF cause insensitivity colorectal tumors to therapy with anti-EGFR monoclonal antibodies, necessitating a genetic testing prior therapy. A biological microchip was developed validated allow detection 19 somatic in genes. The method combines LNA-clamp PCR allele-specific hybridization on detects mutant DNA 100 times wild-type background (1%). total 66 samples isolated from were tested the biochip. Possible associations between status tumor patient's characteristics (age, sex, localization, stage, TMN) assessed statistically. KRAS more common females (P = 0.02) patients distant metastasis 0.04). Other presence patient not observed. proved highly sensitive can be used oncology select who antibodies.